PARIOFORMA
 An international pharmaceutical company commissioned Parioforma to investigate
learnings from recent reimburs...
Upcoming SlideShare
Loading in …5
×

Orphan drugs in emerging markets

434 views

Published on

Market access issues for orphan drugs in Emerging Markets

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
434
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Orphan drugs in emerging markets

  1. 1. PARIOFORMA  An international pharmaceutical company commissioned Parioforma to investigate learnings from recent reimbursement applications for Orphan Drugs in selected Emerging Markets.  Client objectives ◦ Gain a better understanding of the treatment environment for orphan diseases in selected Emerging Markets:  Funding mechanisms  Unmet needs  Current clinical practice and access to care ◦ Gain a better understanding of the Evidence requirements to support the reimbursement of Orphan Drugs in these countries:  Assessment of the importance of trial parameters on the decision to reimburse  Assessment of the importance of clinical parameters on the decision to reimburse ◦ Identify informal practices different to the formal policy described in Government documents ◦ Identify reasons for the non-reimbursement of certain Orphan therapies in recent years  Programme of work ◦ Desk research was used to gain an overview into formal Government published procedures regarding patient access to and the funding of Orphan Drugs ◦ Interviews were conducted with payers and KOLs to confirm and validate official requirements and procedures for the reimbursement of such drugs as well as to gain a more balanced view on official procedures vs. informal practices and the reasons behind recent unsuccessful reimbursement applications ◦ Available evidence was assessed and a report was prepared covering the detailed findings, with key recommendations for the client  Value ◦ The results of the project allowed the client to gain a clear understanding of the parameters that influence access to funding of Orphan Drugs in these markets, enabling them to adapt their global market access strategy for a better fit to emerging markets  For further information, or to discuss your market access, pricing and reimbursement intelligence requirements, contact US now… Parioforma Ltd – 55 Prices Gate – Exhibition Road – London SW7 2PN – United Kingdom www.parioforma.com 1

×